A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness (Q33839248)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

multicenter clinical trial

0 references

prostate cancer

1 reference

based on heuristic

inferred from title

7

object named as

Alan W Partin

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

author name string

Lori J Sokoll

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Martin G Sanda

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ziding Feng

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Jacob Kagan

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Isaac A Mizrahi

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Dennis L Broyles

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sudhir Srivastava

8

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Ian M Thompson

9

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

John T Wei

10

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Zhen Zhang

11

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel W Chan

12

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Cancer Epidemiology, Biomarkers & Prevention

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1193-1200

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Biomarkers for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Prostate-specific antigen in the early detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

PSA and new biomarkers within multivariate models to improve early detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A (-5, -7) proPSA based artificial neural network to detect prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Free prostate-specific antigen in serum is becoming more complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

5 July 2018

A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2867076

29 October 2018

Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20447916

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1055-9965.EPI-10-0007

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33839248&oldid=1571711303"